Shionogi Files for Approval of S-268019, a COVID-19 Recombinant Protein-based Vaccine, in Japan – Shionogi

OSAKA, Japan, November 24, 2022 – Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that it has filed for manufacturing and sales approval of S-268019, a recombinant protein-based preventive vaccine, for use in priming and booster (3rd) doses, against COVID-19, caused by the novel coronavirus (SARS-CoV-2) infection. S-268019 […]

Continue reading

COVID-19 disrupts gut microbiome – National Institutes of Health (.gov)

More »Search Health TopicsQuick LinksMore »Search the NIH GuideQuick LinksMore »Quick LinksMore »Quick LinksMore »Quick LinksMore »Quick LinksNovember 22, 2022The trillions of microbes living in the gut—bacteria, fungi, and viruses—are known collectively as the gut microbiome. Research has shown that changes in gut microbes may contribute to a variety of diseases and conditions.COVID-19 patients often […]

Continue reading
1 110 111 112 113 114 125